A detailed history of Main Street Group, LTD transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Main Street Group, LTD holds 51 shares of IBRX stock, worth $124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51
Holding current value
$124
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 15, 2025

BUY
$1.89 - $3.44 $96 - $175
51 New
51 $0

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $981M
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Main Street Group, LTD Portfolio

Follow Main Street Group, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Main Street Group, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Main Street Group, LTD with notifications on news.